{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T19:14:09Z","timestamp":1754162049617,"version":"3.41.2"},"reference-count":49,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,5]]},"abstract":"<jats:p>Anticoagulation during percutaneous coronary interventions has a rich history that has been shaped by several key clinical trials. The correct choice of anticoagulation during interventions can maximize patient outcomes and ensure a safe procedure. However, in some specific situations, anticoagulation may not be required at all. In this review article, we review the significant clinical trials and current guidelines regarding the use of anticoagulation in the catheterization laboratory and discuss the unique pharmacological aspects of the most commonly used agents, with an emphasis on the specific pharmacokinetic parameters that dictate how these agents are used and monitored. Finally, we discussed the future directions in anticoagulation therapy in coronary artery disease. This review serves as a robust synopsis of the clinical data for practicing clinicians and fellows in training.<\/jats:p>","DOI":"10.1097\/mca.0000000000001095","type":"journal-article","created":{"date-parts":[[2021,8,19]],"date-time":"2021-08-19T16:09:45Z","timestamp":1629389385000},"page":"222-232","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Contemporary use of anticoagulation in the cardiac catheterization laboratory: a review"],"prefix":"10.1097","volume":"33","author":[{"given":"Brent J.","family":"Klinkhammer","sequence":"first","affiliation":[{"name":"Section of Cardiology, Hackensack University Medical Center, Hackensack, New Jersey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandeep","family":"Nathan","sequence":"additional","affiliation":[{"name":"Section of Cardiology, University of Chicago Medicine, Chicago, Illinois, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ankitkumar K.","family":"Patel","sequence":"additional","affiliation":[{"name":"Section of Cardiology, Hackensack University Medical Center, Hackensack, New Jersey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2021,8,17]]},"reference":[{"key":"R1-20250729","doi-asserted-by":"crossref","first-page":"E1025","DOI":"10.3390\/molecules22061025","article-title":"From farm to pharma: an overview of industrial heparin manufacturing methods.","volume":"22","author":"van der Meer","year":"2017","journal-title":"Molecules"},{"key":"R2-20250729","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.1056\/NEJMoa0806450","article-title":"Outbreak of adverse reactions associated with contaminated heparin.","volume":"359","author":"Blossom","year":"2008","journal-title":"N Engl J Med"},{"key":"R3-20250729","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1161\/hq0701.093686","article-title":"Mechanism of action and pharmacology of unfractionated heparin.","volume":"21","author":"Hirsh","year":"2001","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R4-20250729","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/0006-291X(76)90558-1","article-title":"The separation of active and inactive forms of heparin.","volume":"69","author":"Lam","year":"1976","journal-title":"Biochem Biophys Res Commun"},{"key":"R5-20250729","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1182\/blood-2004-03-1092","article-title":"Heparin-activated antithrombin interacts with the autolysis loop of target coagulation proteases.","volume":"104","author":"Yang","year":"2004","journal-title":"Blood"},{"key":"R6-20250729","doi-asserted-by":"crossref","first-page":"64S","DOI":"10.1378\/chest.119.1_suppl.64S","article-title":"Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety.","volume":"119","author":"Hirsh","year":"2001","journal-title":"Chest"},{"key":"R7-20250729","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s11239-015-1314-3","article-title":"Pharmacology of anticoagulants used in the treatment of venous thromboembolism.","volume":"41","author":"Nutescu","year":"2016","journal-title":"J Thromb Thrombolysis"},{"key":"R9-20250729","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1016\/j.jacc.2011.08.007","article-title":"2011 ACCF\/AHA\/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions.","volume":"58","author":"Levine","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"R10-20250729","first-page":"330","article-title":"Reproducibility and variability of activated clotting time measurements in the cardiac catheterization laboratory.","volume":"65","author":"Doherty","year":"2005","journal-title":"Catheter Cardiovasc Interv"},{"key":"R11-20250729","doi-asserted-by":"crossref","first-page":"314","DOI":"10.7861\/clinmedicine.18-4-314","article-title":"The reversal of anticoagulation in clinical practice\u2002.","volume":"18","author":"Thomas","year":"2018","journal-title":"Clin Med (Lond)"},{"key":"R12-20250729","first-page":"95","article-title":"Pharmacological and clinical differences between low-molecular-weight heparins: implications for prescribing practice and therapeutic interchange.","volume":"35","author":"Merli","year":"2010","journal-title":"P T"},{"key":"R14-20250729","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s11239-015-1314-3","article-title":"Pharmacology of anticoagulants used in the treatment of venous thromboembolism [published correction appears in J Thromb Thrombolysis. 2016 Aug;42(2):296-311].","volume":"41","author":"Nutescu","year":"2016","journal-title":"J Thromb Thrombolysis"},{"key":"R15-20250729","doi-asserted-by":"crossref","first-page":"493","DOI":"10.2147\/VHRM.S2455","article-title":"Percutaneous coronary intervention in patients with acute coronary syndrome: focus on bivalirudin.","volume":"4","author":"Ramana","year":"2008","journal-title":"Vasc Health Risk Manag"},{"key":"R16-20250729","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1177\/0897190012442721","article-title":"Comparison of bolus only with bolus plus infusion of bivalirudin in patients undergoing elective percutaneous coronary intervention: a retrospective observational study.","volume":"25","author":"Sheikh-Taha","year":"2012","journal-title":"J Pharm Pract"},{"key":"R17-20250729","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0049-3848(03)00030-6","article-title":"Evaluation of the pharmacological properties and clinical results of the synthetic pentasaccharide (fondaparinux).","volume":"109","author":"Samama","year":"2003","journal-title":"Thromb Res"},{"key":"R19-20250729","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1056\/NEJMoa052711","article-title":"Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention.","volume":"355","author":"Montalescot","year":"2006","journal-title":"N Engl J Med"},{"key":"R20-20250729","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1093\/eurheartj\/ehn008","article-title":"Impact of anticoagulation levels on outcomes in patients undergoing elective percutaneous coronary intervention: insights from the STEEPLE trial.","volume":"29","author":"Montalescot","year":"2008","journal-title":"Eur Heart J"},{"key":"R21-20250729","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1001\/jama.289.7.853","article-title":"Bivalirudin and provisional glycoprotein IIb\/IIIa blockade compared with heparin and planned glycoprotein IIb\/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial.","volume":"289","author":"Lincoff","year":"2003","journal-title":"JAMA"},{"key":"R22-20250729","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1056\/NEJMoa0802944","article-title":"Bivalirudin versus unfractionated heparin during percutaneous coronary intervention.","volume":"359","author":"Kastrati","year":"2008","journal-title":"N Engl J Med"},{"key":"R23-20250729","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1161\/01.CIR.0000158485.70761.67","article-title":"Randomized, blinded trial comparing fondaparinux with unfractionated heparin in patients undergoing contemporary percutaneous coronary intervention: Arixtra Study in Percutaneous Coronary Intervention: a Randomized Evaluation (ASPIRE) Pilot Trial.","volume":"111","author":"Mehta","year":"2005","journal-title":"Circulation"},{"key":"R24-20250729","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1056\/NEJMoa055443","article-title":"Comparison of fondaparinux and enoxaparin in acute coronary syndromes.","volume":"354","author":"Yusuf","year":"2006","journal-title":"N Engl J Med"},{"key":"R25-20250729","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.ahj.2004.06.002","article-title":"Elective percutaneous coronary intervention using broad-spectrum antiplatelet therapy (eptifibatide, clopidogrel, and aspirin) alone, without scheduled unfractionated heparin or other antithrombin therapy.","volume":"149","author":"Denardo","year":"2005","journal-title":"Am Heart J"},{"key":"R26-20250729","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.amjcard.2007.04.057","article-title":"Efficacy and safety of triple antiplatelet therapy with and without concomitant anticoagulation during elective percutaneous coronary intervention (the REMOVE trial).","volume":"100","author":"Valencia","year":"2007","journal-title":"Am J Cardiol"},{"key":"R27-20250729","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.jacc.2008.07.026","article-title":"The CIAO (Coronary Interventions Antiplatelet-based Only) Study: a randomized study comparing standard anticoagulation regimen to absence of anticoagulation for elective percutaneous coronary intervention.","volume":"52","author":"Stabile","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"R28-20250729","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/eurheartj\/ehy394","article-title":"2018 ESC\/EACTS Guidelines on myocardial revascularization.","volume":"40","author":"Neumann","year":"2019","journal-title":"Eur Heart J"},{"key":"R29-20250729","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1016\/S0140-6736(00)02324-2","article-title":"Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis.","volume":"355","author":"Eikelboom","year":"2000","journal-title":"Lancet"},{"key":"R30-20250729","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1016\/j.jacc.2014.09.017","article-title":"2014 AHA\/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines.","volume":"64","author":"Amsterdam","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"R31-20250729","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1093\/eurheartj\/ehaa575","article-title":"2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation.","volume":"42","author":"Collet","year":"2020","journal-title":"Eur Heart J"},{"key":"R32-20250729","first-page":"45","article-title":"Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial.","volume":"292","author":"Ferguson","year":"2004","journal-title":"JAMA"},{"key":"R33-20250729","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1001\/jama.292.1.55","article-title":"Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial.","volume":"292","author":"Blazing","year":"2004","journal-title":"JAMA"},{"key":"R34-20250729","doi-asserted-by":"crossref","first-page":"e78","DOI":"10.1016\/j.jacc.2012.11.019","article-title":"2013 ACCF\/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines.","volume":"61","author":"O\u2019Gara","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"R35-20250729","doi-asserted-by":"crossref","first-page":"e006084","DOI":"10.1161\/CIRCINTERVENTIONS.118.006084","article-title":"Activated clotting time to guide heparin dosing in non-ST-segment-elevation acute coronary syndrome patients undergoing percutaneous coronary intervention and treated with IIb\/IIIa inhibitors: impact on ischemic and bleeding outcomes: insights from the TAO trial.","volume":"11","author":"Dillinger","year":"2018","journal-title":"Circ Cardiovasc Interv"},{"key":"R36-20250729","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1056\/NEJMoa062437","article-title":"Bivalirudin for patients with acute coronary syndromes.","volume":"355","author":"Stone","year":"2006","journal-title":"N Engl J Med"},{"key":"R37-20250729","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMoa1706443","article-title":"Bivalirudin versus heparin monotherapy in myocardial infarction.","volume":"377","author":"Erlinge","year":"2017","journal-title":"N Engl J Med"},{"key":"R38-20250729","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1001\/jama.2010.1320","article-title":"Low-dose vs standard-dose unfractionated heparin for percutaneous coronary intervention in acute coronary syndromes treated with fondaparinux: the FUTURA\/OASIS-8 randomized trial.","volume":"304","author":"Steg","year":"2010","journal-title":"JAMA"},{"key":"R39-20250729","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","article-title":"2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC).","volume":"39","author":"Ibanez","year":"2018","journal-title":"Eur Heart J"},{"key":"R40-20250729","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1001\/jama.295.13.joc60038","article-title":"Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial.","volume":"295","author":"Yusuf","year":"2006","journal-title":"JAMA"},{"key":"R41-20250729","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/S0140-6736(11)60876-3","article-title":"Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: the international randomised open-label ATOLL trial.","volume":"378","author":"Montalescot","year":"2011","journal-title":"Lancet"},{"key":"R42-20250729","doi-asserted-by":"crossref","first-page":"e553","DOI":"10.1136\/bmj.e553","article-title":"Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention: systematic review and meta-analysis.","volume":"344","author":"Silvain","year":"2012","journal-title":"BMJ"},{"key":"R43-20250729","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0140-6736(09)61484-7","article-title":"Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial.","volume":"374","author":"Mehran","year":"2009","journal-title":"Lancet"},{"key":"R44-20250729","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa1311096","article-title":"Bivalirudin started during emergency transport for primary PCI.","volume":"369","author":"Steg","year":"2013","journal-title":"N Engl J Med"},{"key":"R45-20250729","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa1507854","article-title":"Bivalirudin or unfractionated heparin in acute coronary syndromes.","volume":"373","author":"Valgimigli","year":"2015","journal-title":"N Engl J Med"},{"key":"R46-20250729","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(14)60924-7","article-title":"Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial.","volume":"384","author":"Shahzad","year":"2014","journal-title":"Lancet"},{"key":"R47-20250729","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1001\/jama.2015.2323","article-title":"Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: the BRIGHT randomized clinical trial.","volume":"313","author":"Han","year":"2015","journal-title":"JAMA"},{"key":"R48-20250729","first-page":"1240","article-title":"Meta-analysis of bivalirudin versus heparin in transradial coronary interventions.","volume":"96","author":"Kheiri","year":"2020","journal-title":"Catheter Cardiovasc Interv"},{"key":"R49-20250729","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1161\/CIRCULATIONAHA.112.097014","article-title":"Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials.","volume":"125","author":"Bangalore","year":"2012","journal-title":"Circulation"},{"key":"R50-20250729","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/S0140-6736(11)60404-2","article-title":"Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial.","volume":"377","author":"Jolly","year":"2011","journal-title":"Lancet"},{"key":"R51-20250729","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.jcmg.2015.11.025","article-title":"Clinical Use of coronary CTA-derived FFR for decision-making in stable CAD.","volume":"10","author":"N\u00f8rgaard","year":"2017","journal-title":"JACC Cardiovasc Imaging"},{"key":"R52-20250729","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1160\/TH15-01-0061","article-title":"Peri-procedural use of rivaroxaban in elective percutaneous coronary intervention to treat stable coronary artery disease. The X-PLORER trial.","volume":"114","author":"Vranckx","year":"2015","journal-title":"Thromb Haemost"}],"container-title":["Coronary Artery Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MCA.0000000000001095","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T18:05:53Z","timestamp":1753812353000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MCA.0000000000001095"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,17]]},"references-count":49,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/mca.0000000000001095","relation":{},"ISSN":["0954-6928"],"issn-type":[{"type":"print","value":"0954-6928"}],"subject":[],"published":{"date-parts":[[2021,8,17]]}}}